首页> 外文期刊>Stem Cell Research & Therapy >Progress in mesenchymal stem cell–based therapy for acute liver failure
【24h】

Progress in mesenchymal stem cell–based therapy for acute liver failure

机译:间充质干细胞治疗急性肝衰竭的研究进展

获取原文
           

摘要

Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only curative treatment for acute liver failure is liver transplantation, but there are many restrictions on the application of liver transplantation. In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. Several types of stem cells have been used to study liver diseases; mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure.
机译:急性肝衰竭是一种威胁生命的临床综合征,其特征是肝细胞坏死迅速发展,导致高死亡率和资源成本。多种治疗急性肝衰竭的策略仅能预防并发症并降低疾病进展。急性肝衰竭的唯一治疗方法是肝移植,但是对肝移植的应用存在很多限制。近年来,越来越多的研究表明干细胞可以有效治疗急性肝衰竭。几种类型的干细胞已被用于研究肝脏疾病。间充质干细胞是最常用的,因为它们易于获得并且没有伦理问题。本文的目的是回顾有关急性肝衰竭中间充质干细胞治疗机制的最新知识,讨论治疗间充质干细胞的临床前和临床研究的最新进展,并总结间充质干细胞的方法学改进移植治疗肝衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号